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Unfinished Business in Preventing
Alzheimer Disease
By law, the United States has a plan to address Alzhei-
mer disease.1 The first of the National Alzheimer Proj-
ect Act’s 5 goals is the discovery by 2025 of interven-
tions that prevent and effectively treat the disease. The
eTable in the Supplement summarizes 5 current preven-
tion trials, most supported jointly by the National Insti-
tutes of Health and pharmaceutical companies.2 This
alignment of public and private interests, shared re-
sources, and the willingness of thousands of cogni-
tively normal adults with heightened genetic or bio-
marker risk of Alzheimer disease to enroll in trials are
signs of progress. The plan is missing an important
strategy, however.
The aim of the medications being tested is to pre-
vent, or significantly delay, the onset of symptomatic
Alzheimer disease. Only 1 of the 5 trials, however
(Generation; NCT02565511), uses measures of sympto-
matic disease or function as a coprimary end point. In-
stead, most use only a measure of cognition, called an
"intermediate clinical end point" because it does not
establish meaningful clinical benefit.3 The US Food and
Drug Administration’s (FDA) accelerated approval guid-
ance, developed initially in response to public demand
to speed HIV treatments, permits this evaluation strat-
egy for serious and life-threatening diseases, such as
Alzheimer disease.4 After approval, the expectation is
that evidence will be gathered to establish meaningful
clinical benefit.3 The national Alzheimer disease plan
lacks a strategy to decide what this evidence is and how
it should be gathered and interpreted.
A strategy for gathering and interpretating infor-
mation is needed before the FDA approves a new drug
to prevent Alzheimer disease. After approval, the drug
will be marketed under a brand name, and public and
private interests and resources will begin to diverge.
Recent controversies over the cost of oncology medi-
cations show how private interests shape the evidence
that establishes that a medication has meaningful clini-
cal benefit, and therefore its price.5
The Anti-Amyloid Treatment in Asymptomatic
Alzheimer Study (A4 Study; NCT02008357) offers a case
study. The A4 Study is testing whether 3 years of treat-
ment with solanezumab, a drug designed to decrease
brain amyloid deposition and which is also being studied
in persons with mild–stage Alzheimer disease dementia,
slows the rate of cognitive decline in cognitively normal
adults ages 65 to 85 years who have evidence of el-
evated brain amyloid by positron emission tomography
scanning. The primary end point of the A4 Study is the
Alzheimer Disease Cooperative Study–Preclinical
Alzheimer Cognitive Composite (ADCS–PACC), a com-
posite of 4 cognitive tests (2 measures of memory, a
measure of executive function, and the Mini-Mental State
Exam [MMSE]). What if the trial shows that, compared
with placebo, persons on the study drug have slower cog-
nitive decline? How is it established that this is a mean-
ingful clinical benefit? At present, it is not known whether
a statistically significant difference in ADCS-PACC scores
between patients in different study groups would trans-
late to a clinically meaningful improvement in current or
future ability to perform important cognitive tasks, such
as managing finances or taking medications.
Among chronic diseases of aging, Alzheimer dis-
ease is unique. About three-quarters of the economic
effect is related to the need for long-term daily care.6
Therefore, the benefit of a prevention therapy is shown
if it allows people to remain independent (ie, not de-
mented) longer than if they did not take the treatment.
Studies should track functional outcomes such as the need
for care (either as supervision or assistance) from family
or professionals at home or in a long-term care facility.
Answers to 3 questions will help to quantify these
outcomes: (1) Is there a slowing of the trajectory of cog-
nitive decline after the onset of dementia? (2) Does treat-
ment lead to a lengthening of the mild or severe stages
of dementia? (3) Does treatment delay death and, if so,
is treatment associated with compression or expan-
sion of the time living with dementia?
A trial that measures 36 months of treatment can-
not answer these questions because the outcomes that
establish the efficacy of a drug for preventing Alzheimer
disease—maintenance of independent function and de-
creased caregiving requirements—may not become ap-
parent for considerably more than 3 years. Decision ana-
lytic models for the ADCS-PACC outcome can be used to
extrapolate effects on other outcomes in the treated
group vs the untreated group.7 Such models can provide
estimates of long-term treatment benefits under differ-
ent assumptions about how the intermediate clinical end
point relates to clinical outcomes. Decision analytic mod-
els are not a substitute for clinical outcomes, however.
The participants in Alzheimer disease prevention
trials should continue to be followed in observational
cohort studies. Tracking functional outcomes (for
example, managing finances, medications, and driv-
ing), as well as scores on cognitive tests, should make it
easier to determine whether presymptomatic treat-
ments actually prevent disability and dementia. It is also
important to study the relationships between cognitive
and clinical outcomes in patients who are more repre-
sentative than those in clinical trials. This might be pos-
sible by adding the cognitive measures used in preven-
tion trials to existing longitudinal cohorts, such as the
Medicare Current Beneficiary Survey, the Framingham
Heart Study, the Health and Retirement Study, and the
National Health and Aging Trends Study.
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The national strategy to establish the benefits of a treatment
to prevent Alzheimer disease should address 4 considerations.
First, the claim that such a treatment provides clinically meaningful
benefit will engage competing interests: the interest of the public—
patients, families, and public programs such as Medicare—who
want efficacious and affordable treatments and private, for-profit
interests of companies who own treatments and understandably
also want to maximize the return on their investments. The
National Alzheimer Project Act provides a public forum to assemble
these interests, prespecify approaches to interpret and weigh
evidence, and to make data and data analyses publicly available.
Second, older adults who receive therapies to prevent Alzhei-
mer disease will typically have chronic diseases (eg, cardiovascular
disease) that increase their risk of both cognitive decline and death.
A treatment-related delay in the onset of dementia should occur be-
fore an individual is likely to die from another cause. Balancing the
benefits and risks of preventing dementia should include consider-
ation of the competing risk of death from other causes.
Third, persons with Alzheimer disease are said to die twice, first
in mind and then in body years later. The judgment that a treatment
is valuable because patients lived longer should align with other val-
ues such as whether autonomy and quality of life are preserved. For
Alzheimer disease, patient-reported measures of autonomy and qual-
ity of life are problematic. Even at the mild cognitive impairment stage,
patients often underreport the severity of functional losses.8 Infor-
mation from spouses or adult children may be unavailable or of un-
certain accuracy. Automated monitoring of financial tasks or driving
might detect the earliest symptoms, but software that monitors, ag-
gregates, and analyzes financial transactions or driving behaviors raises
concerns about intrusions into privacy and independence and also
setting validated thresholds that justify intervention.
Fourth, patients may discontinue the medication. If discontinu-
ation rates of Alzheimer prevention drugs are the same as for car-
diovascular drugs (5% to 10% per year), the treatment benefit, if
there is one, is likely to decrease over time.9 The discontinuation rates
for investigational agents are not yet known; however, if they are
to prevent the onset of symptoms, they may need to be taken on a
regular basis for years.
Symptomatic Alzheimer disease is common, debilitating, and
costly. Although a national plan to prevent symptomatic disease can
address these problems, the plan needs an additional strategy to
show that expedited approval of new medications will truly
improve the lives of the millions of patients with asymptomatic
Alzheimer disease who may take them.
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